Compounds > lonafarnib
Page last updated: 2024-09-04

lonafarnib and dinaciclib

lonafarnib has been researched along with dinaciclib in 1 studies

Compound Research Comparison

Studies
(lonafarnib)		Trials
(lonafarnib)		Recent Studies (post-2010)
(lonafarnib)		Studies
(dinaciclib)		Trials
(dinaciclib)		Recent Studies (post-2010) (dinaciclib)
224349013312129

Protein Interaction Comparison

ProteinTaxonomylonafarnib (IC50)dinaciclib (IC50)
Cyclin-T1Homo sapiens (human)0.0272
Cyclin-KHomo sapiens (human)0.0227
Cyclin-dependent kinase 1Homo sapiens (human)0.0162
Cyclin-dependent kinase 4Homo sapiens (human)0.0742
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.049
Cyclin-A2Homo sapiens (human)0.002
G1/S-specific cyclin-D1Homo sapiens (human)0.119
G1/S-specific cyclin-E1Homo sapiens (human)0.0028
Cyclin-dependent kinase 2Homo sapiens (human)0.0074
Aldo-keto reductase family 1 member C3Homo sapiens (human)0.23
Cyclin-dependent kinase 8Homo sapiens (human)0.0039
Glycogen synthase kinase-3 alphaHomo sapiens (human)0.414
Glycogen synthase kinase-3 betaHomo sapiens (human)0.324
Cyclin-dependent kinase 7Homo sapiens (human)0.1273
Cyclin-dependent kinase 9Homo sapiens (human)0.0227
Cyclin-HHomo sapiens (human)0.17
CDK-activating kinase assembly factor MAT1Homo sapiens (human)0.17
Cyclin-A1Homo sapiens (human)0.003
Cyclin-dependent-like kinase 5 Homo sapiens (human)0.011
Heat shock factor protein 1Homo sapiens (human)0.007
Cyclin-dependent kinase 13Homo sapiens (human)0.021
Cyclin-dependent kinase 5 activator 1Homo sapiens (human)0.0219
Cyclin-dependent kinase 12Homo sapiens (human)0.0323

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Laufer, S; Pillaiyar, T1

Reviews

1 review(s) available for lonafarnib and dinaciclib

ArticleYear
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Protein Kinase Inhibitors; SARS-CoV-2; Signal Transduction; Virus Replication

2022